All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

CAR T-Cell Therapy for Solid Tumors: Leveraging Lessons From Hematologic Malignancies

April 9th 2025

As we plan for a future with solid tumor CAR T-cell therapy, we should be mindful of lessons learned from CAR T-cell agents for hematologic malignancies.

Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in Metastatic NSCLC

April 9th 2025

Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC

April 8th 2025

Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.

Roswell Park-Led Research Reveals a Hidden Vulnerability of Lung Cancer

April 8th 2025

Sayan Chakraborty, PhD and team focus on targeting agrin, a protein that promotes treatment resistance/relapse.

FDA Approves Nivolumab Plus Ipilimumab for dMMR/MSI-H Metastatic CRC

April 8th 2025

The FDA has granted approval to nivolumab plus ipilimumab for the treatment of patients with dMMR/MSI-H metastatic colorectal cancer.

Tambiciclib Generates Potential OS Benefit in R/R AML

April 8th 2025

Tambiciclib generated a median overall survival of 8.8 months in patients with relapsed/refractory acute myeloid leukemia.

Dato-DXd Secures EU Approval for Pretreated HR+/HER2– Metastatic Breast Cancer

April 8th 2025

The European Commission approved Dato-DXd for advanced HR-positive, HER2-negative breast cancer after endocrine therapy and chemotherapy.

FDA Approval Is Sought for Ziftomenib in NMP1-Mutant R/R AML

April 8th 2025

The FDA has received an NDA for ziftomenib in relapsed/refractory NMP1-mutant acute myeloid leukemia.

Immunogenomic Properties Predict Exceptional Responses to Immune Checkpoint Inhibition in RCC

April 8th 2025

Clonal neoantigen load was significantly associated with promising responses to PD-1/PD-L1 and CTLA-4 combination therapy in RCC.

Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer

April 8th 2025

Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.

R-DA-EDOCH/R-DHAP Induction Yields Responses and MRD Negativity in Young, High-Risk MCL Population

April 8th 2025

Induction R-DA-EDOCH/R-DHAP therapy yields high rates of CR, overall response, and MRD negativity in young patients with newly diagnosed, high-risk MCL.

Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC

April 7th 2025

Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.

Bel-Sar Shows Tolerability and Preliminary Antitumor Activity in NMIBC

April 7th 2025

Belzupacap sarotalocan demonstrated a favorable safety profile and early signs of biological activity in patients with NMIBC.

VXM01 Plus Avelumab Is Safe and Shows Preliminary Clinical Activity in Recurrent Glioblastoma

April 7th 2025

The combination of VXM01 and avelumab was well tolerated and has the potential to generate clinically meaningful responses in recurrent glioblastoma.

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance

April 7th 2025

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

EC Expands SC Daratumumab’s Indication for Use in All Transplant Eligibility Settings in Newly Diagnosed Myeloma

April 7th 2025

The European Commission approved subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma, regardless of transplant eligibility.

Subcutaneous Amivantamab Wins EU Approval in Multiple EGFR+ Advanced NSCLC Indications

April 7th 2025

The European Commission has approved subcutaneous amivantamab in multiple indications in advanced EGFR-mutant non–small cell lung cancer.

Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer

April 7th 2025

IHC staining is top of mind for the use of ADCs in cervical cancer management; however, the specific indications for each agent must be considered.

Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells

April 7th 2025

A study showed transcription factor networks disproportionately enrich for heritability of blood cell phenotypes.

ctDNA-Guided Approaches Reveal Effective Adjuvant Agents in MRD+ CRC

April 7th 2025

Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.